As Catalent sets up shop in a new headquarters and refines its corporate image under the ownership of Novo Holdings, the CDMO ...

Detailed price information for Sarepta Therapeutics (SRPT-Q) from The Globe and Mail including charting and trades.

Ten stocks soared higher on Wednesday, mirroring a broader market rally, as investors continued to take path from a flurry of ...

The administration, as well as HHS, publicly praised Marty Makary’s leadership despite persistent upheaval at the agency.

Sarepta Therapeutics (SRPT) surged after Mizuho upgraded to Outperform, citing strong Elevidys uptake and gene therapy ...

According to reporting from Reuters, reviewers at the agency pointed to an inability to differentiate from placebo to justify rejecting the drug, but an FDA office director approved the drug anyway.

Mizuho upgraded Sarepta Therapeutics Inc to Outperform from Neutral and raised its price target to $26 from $19, citing stronger-than-expected sales of its gene therapy Elevidys and growing confidence ...

Sarepta Therapeutics stock has seen its consensus analyst price target trimmed slightly, dropping from $22.88 to $21.55 per share in light of recent developments and research updates. This shift ...

Sarepta stock already had declined 80% for the year before Tuesday’s selloff. It has tumbled amid a Food and Drug ...

Children’s Hospital Los Angeles (CHLA) is expanding its safety protocol for patients receiving Elevidys®, the FDA-approved ...

Sarepta Therapeutics, Inc. faces revenue decline, trial setbacks, and FDA decisions. Click for SRPT risks, outlook, and if ...